Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 21, 2020The Lancet OncologyOpen Access

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMichiel S. van der HeijdenMGMatthew D. GalskyYLYohann Loriot

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Heijden et al. (2020) studied this question.

synapsesocial.com/papers/6aa531d74dd50f8a0764af6bhttps://doi.org/10.1016/s1470-2045(20)30541-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer2020 · 635 citations
  2. 2Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis2020 · 45 citations
  3. 3Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer2016 · 846 citations
  4. 4Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy2019 · 44 citations
  5. 5Versatile Tests for Comparing Survival Curves Based on Weighted Log-rank Statistics2016 · 82 citations